BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11446729)

  • 1. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems.
    Sperr WR; Wimazal F; Kundi M; Fonatsch C; Thalhammer-Scherrer R; Schernthaner GH; Schwarzinger I; Haas OA; Geissler K; Lechner K; Valent P
    Ann Hematol; 2001 May; 80(5):272-7. PubMed ID: 11446729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
    Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
    Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study.
    Lee JJ; Kim HJ; Chung IJ; Kim JS; Sohn SK; Kim BS; Lee KH; Kwak JY; Park YH; Ahn JS; Park YS
    Leuk Res; 1999 May; 23(5):425-32. PubMed ID: 10374856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
    Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
    Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
    Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
    Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
    Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes.
    Wimazal F; Sperr WR; Kundi M; Meidlinger P; Fonatsch C; Jordan JH; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Lechner K; Valent P
    Leuk Res; 2001 Apr; 25(4):287-94. PubMed ID: 11248325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
    Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
    Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
    Rubio-Felix D; Giraldo P; Franco E; Gimeno J; Giralt M
    Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
    Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
    Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system.
    Jaiyesimi IA; Friedline JA; Mattson JC; Gyorfi T; Davis BH; Balasubramaniam M; Al-Khalili A; Burdakin J; Decker D; Zakalik D; Neumann K; Wilner F
    Leuk Res; 2000 May; 24(5):417-26. PubMed ID: 10785264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.
    Lee JH; Lee JH; Shin YR; Lee JS; Kim WK; Chi HS; Park CJ; Seo EJ; Lee KH
    Leukemia; 2003 Feb; 17(2):305-13. PubMed ID: 12592327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
    Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
    Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
    Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.